MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.840
-0.070
-2.41%
After Hours: 2.800 -0.04 -1.41% 17:31 09/21 EDT
OPEN
2.990
PREV CLOSE
2.910
HIGH
2.990
LOW
2.730
VOLUME
122.26K
TURNOVER
--
52 WEEK HIGH
8.15
52 WEEK LOW
2.570
MARKET CAP
23.85M
P/E (TTM)
3.283
1D
5D
1M
3M
1Y
5Y
5 Value Stocks In The Healthcare Sector
What Defines a Value Stock?
Benzinga · 09/06 14:27
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conferen...
GlobeNewswire · 09/03 11:30
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday.
Benzinga · 09/01 16:00
Why Is Bellicum Stock Moving Higher On Wednesday?
Benzinga · 09/01 13:01
BRIEF-Bellicum And MD Anderson Announce Additional License Agreement For Use Of Caspacide Safety Switch
reuters.com · 09/01 11:36
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe Safety Switch
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and
Benzinga · 09/01 11:34
Bellicum Pharmaceuticals, MD Anderson Cancer Center Enter Licensing Deal on CaspaCIDe Safety Switch
MT Newswires · 09/01 10:07
Bellicum Pharmaceuticals Q2 EPS $(0.22) Up From $(7.81) YoY
Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly losses of $(0.22) per share. This is a 97.18 percent increase over losses of $(7.81) per share from the same period last year.
Benzinga · 08/12 21:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLCM. Analyze the recent business situations of Bellicum Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLCM stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 9.33M
% Owned: 111.11%
Shares Outstanding: 8.40M
TypeInstitutionsShares
Increased
4
267.50K
New
4
27.73K
Decreased
8
81.67K
Sold Out
3
26.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Independent Director
James Brown
President/Chief Executive Officer/Director
Richard Fair
Independent Director
James Daly
Independent Director
Stephen Davis
Independent Director
Reid Huber
Independent Director
Judith Klimovsky
Independent Director
Jon Stonehouse
No Data
  • All
  • Financials
  • Insiders
More
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. The Company's product candidates include BPX-601 and BPX-603. The BPX-601, is an autologous GoCAR-T product candidate containing iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). The BPX-603, is a controllable dual-switch autologous GoCAR-T product candidate, which incorporates both the iMC activation switch and the CaspaCIDe safety switch.

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLCM stock methods without spending real money on the virtual paper trading platform.